Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies... Show more
Get AI intraday alerts
A.I. Advisor
published Earnings
ADAG is expected to report earnings to fall 69.23% to -7 cents per share on December 02
Q3'26
Est.
$-0.08
Q2'26
Missed
by $0.07
Q1'26
Beat
by $0.15
Q4'25
Beat
by $0.15
Q2'25
Beat
by $0.10
The last earnings report on August 12 showed earnings per share of -25 cents, missing the estimate of -18 cents. With 117.41K shares outstanding, the current market capitalization sits at 134.29M.